Key Summary
- UK is joining the European Rare Diseases Research Alliance.
- Rare diseases, while individually uncommon, are collectively significant.
- For UK healthcare leaders and professionals, ERDERA presents a range of opportunities.
The UK has formally joined the European Rare Diseases Research Alliance (ERDERA), marking a pivotal moment for international scientific collaboration and offering renewed hope to millions of people affected by rare conditions.
Rare diseases, while individually uncommon, are collectively significant. By definition, they affect fewer than five in 10,000 people per condition.
However, with over 7,000 identified rare diseases, the combined impact is substantial - touching around 3.5 million people in the UK and more than 300 million worldwide.
This vast scale underlines the critical need for global partnerships to accelerate both research and clinical progress.
By joining ERDERA, UK researchers gain direct access to the world’s largest rare disease research network, comprising 180 organisations across 37 countries, including EU member states, Canada, and Switzerland.
This move enables greater participation in international clinical trials, fostering rapid innovation in diagnostics and treatments for patients with rare conditions.
The Department of Health and Social Care, through the National Institute for Health and Care Research (NIHR), has taken a leading role as the first UK funder to co-finance calls for proposals under the alliance, signaling a strong commitment to embedding UK science within global research efforts.
Professor Lucy Chappell, CEO of the NIHR, emphasised the significance of this collaboration: “Rare diseases can have a serious impact on patients and families, and progress depends on countries working together.
“Through ERDERA, UK researchers will be able to take part in international studies and clinical trials that aim to improve diagnosis and treatment of rare diseases. This partnership brings together expertise and resources from many countries, helping research move faster and improve outcomes for patients.”
This development strengthens UK-EU research ties and enhances the UK’s position within a broader portfolio of Horizon Europe health partnerships.
For healthcare leaders and professionals, the UK’s participation in ERDERA presents a range of immediate opportunities. UK institutions can now join multinational studies, thereby increasing diverse patient access to emerging therapies.
